Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.

Why Mylan (MYL) Could Beat Earnings Estimates Again

by Zacks Equity Research

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up

by Zacks Equity Research

Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.

Indrajit Bandyopadhyay headshot

Uncertainty Looms Large Over Generic Drug Industry Players

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.

Mylan (MYL) Obtains FDA Approval for Biosimilar of Humira

by Zacks Equity Research

Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.

Endo (ENDP) Obtains FDA Approval for Cellulite Treatment

by Zacks Equity Research

Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.

Novartis Discontinues HCQ Study Due to Enrollment Challenges

by Zacks Equity Research

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent

by Zacks Equity Research

Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.

Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan

by Zacks Equity Research

The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.

Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study

by Zacks Equity Research

Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.

Momenta (MNTA) Up on Positive Data From Generalized MG Drug

by Zacks Equity Research

Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers

by Zacks Equity Research

FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.

Mylan & Biocon's Semglee Wins FDA Approval for Diabetes

by Zacks Equity Research

Mylan (MYL) and partner Biocon gains FDA approval for diabetes treatment, Semglee.

Mylan (MYL) Up 13.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Research Reports for Intel, Adobe & AMD

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Intel Corporation (INTC), Adobe Inc. (ADBE) and Advanced Micro Devices, Inc. (AMD).

Supriyo Bose headshot

Markets Set Out on Long Journey to Recovery: 4 ROE Picks

by Supriyo Bose

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

Is Mylan (MYL) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

by Zacks Equity Research

Mylan (MYL) beats on Q1 earnings but misses on sales.

Mylan (MYL) Q1 Earnings Top Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Mylan (MYL) This Earnings Season?

by Zacks Equity Research

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.

Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling

by Zacks Equity Research

Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.